يعرض 1 - 20 نتائج من 103 نتيجة بحث عن '"Trojer, P."', وقت الاستعلام: 0.45s تنقيح النتائج
  1. 1
    Report
  2. 2
    Report
  3. 3
  4. 4
  5. 5
    Periodical
  6. 6
  7. 7
    Report
  8. 8
    Report
  9. 9
    Report
  10. 10
  11. 11
    Periodical
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
  15. 15
    Periodical
  16. 16
    Conference

    المساهمون: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia

    Relation: Palandri F, Mascarenhas J, Harrison C, Patriarca A, Devos T, Rampal R, et al. CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY. Haematologica. 2021;106(10):5-6.; http://hdl.handle.net/10541/624818; Haematologica

  17. 17
    Conference

    المساهمون: Cancer Research UK Manchester Institute, University of Manchester, The Christie Hospital, Manchester

    Relation: Somervaille T, Verstovsek S, Bose P, Mascarenhas J, Kremyanskaya M, Hoffman R, et al. CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as add-on to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: Update of MANIFEST phase 2 study. British Journal of Haematology. 2021;193:98-99.; http://hdl.handle.net/10541/624074; British Journal of Haematology

  18. 18
    Conference

    المساهمون: Oxford University Hospitals NHS Foundation Trust, Oxford

    Relation: Mead A, Mascarenhas J, Kremyanskaya M, Hoffman R, Talpaz M, Patriarca A, et al. CPI-0610, A BROMODOMAIN and EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, in COMBINATION with RUXOLITINIB, in JAK-INHIBITOR-NA VE MYELOFIBROSIS PATIENTS: UPDATE of MANIFEST PHASE 2 STUDY. British Journal of Haematology. 2021;193:96.; http://hdl.handle.net/10541/624073; British Journal of Haematology

  19. 19
    Book
  20. 20
    Academic Journal